Health-related quality of life in Thai patients with chronic hepatitis B

被引:0
作者
Chantrakul, Ratthanan [1 ]
Sripongpun, Pimsiri [1 ]
Pattarapuntakul, Tanawat [1 ]
Chamroonkul, Naichaya [1 ]
Kongkamol, Chanon [2 ,3 ]
Phisalprapa, Pochamana [4 ]
Kaewdech, Apichat [1 ]
机构
[1] Prince Songkla Univ, Fac Med, Div Internal Med, Gastroenterol & Hepatol Unit, 15 Karnjanavanich Rd, Hat Yai 90110, Songkhla, Thailand
[2] Prince Songkla Univ, Fac Med, Div Family & Prevent Med, Hat Yai, Thailand
[3] Prince Songkla Univ, Fac Med, Div Digital Innovat & Data Analyt, Hat Yai, Thailand
[4] Mahidol Univ, Dept Med, Div Ambulatory Med, Fac Med,Siriraj Hosp, 2 Wanglang Rd, Bangkok 10700, Thailand
来源
GASTROENTEROLOGY REPORT | 2024年 / 12卷
关键词
health state utilities; chronic hepatitis B; health-related quality of life; EQ-5D-5L; CLINICAL-PRACTICE GUIDELINES; MANAGEMENT;
D O I
10.1093/gastro/goae015
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Chronic hepatitis B (CHB) significantly impacts the health-related quality of life (HRQoL), but remains underexplored in the Thai population. Health state utilities (HSU) are indicators reflecting HRQoL which serve as fundamental inputs for economic evaluation analyses. This study aimed at assessing differences in HRQoL across five CHB stages in Thai patients, including non-cirrhotic CHB, compensated cirrhosis, decompensated cirrhosis, early-/intermediate-stage hepatocellular carcinoma (HCC) and advanced-/terminal-stage HCC. Methods: We conducted a cross-sectional study to collect HRQoL data from patients with CHB at five stages. The study included patients with CHB who were followed up at a super-tertiary care centre between March 2021 and February 2022. The participants completed the EQ-5D-5L questionnaire and provided demographic data. Disease stage and relevant data were obtained from medical records. HSU and Euroqol-visual analogue scale (EQ-VAS) scores, calculated using Thai-specific conversion coefficients, were assessed. Results: Among 422 patients, 236 did not have cirrhosis, 92 had compensated cirrhosis, 13 had decompensated cirrhosis, 55 had early-/intermediate-stage HCC, and 26 had advanced-/terminal-stage HCC. The HSU scores for non-cirrhotic, compensated cirrhosis, decompensated cirrhosis, early-/intermediate-stage HCC and advanced-/terminal-stage HCC were 0.95 +/- 0.08, 0.89 +/- 0.16, 0.79 +/- 0.19, 0.89 +/- 0.12 and 0.52 +/- 0.39, respectively. Similarly, the EQ-VAS scores for various CHB stages were 83.56 +/- 12.90, 80.48 +/- 13.03, 68.76 +/- 17.40, 79.00 +/- 14.38 and 62.92 +/- 20.62, respectively. A significant correlation (r = 0.469, P < 0.001) was observed between the HSU and EQ-VAS scores. The disease progression led to a notable HSU decline, particularly in the advanced-/terminal-stage HCC group (regression coefficient: -0.436, P < 0.001). The EQ-VAS scores indicated reduced quality of life in advanced liver disease. Conclusions: Later CHB stages compromise the HRQoL. Decompensated cirrhosis and advanced-/terminal-stage HCC profoundly affect physical health and quality of life, whereas patients with compensated cirrhosis and early-/intermediate-stage HCC report better HRQoL.
引用
收藏
页数:7
相关论文
共 26 条
  • [1] [Anonymous], 2023, Hepatitis B
  • [2] Preference-based measures of health-related quality of life in congenital mobility impairment: a systematic review of validity and responsiveness
    Bray, Nathan
    Spencer, Llinos Haf
    Edwards, Rhiannon Tudor
    [J]. HEALTH ECONOMICS REVIEW, 2020, 10 (01)
  • [3] EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
    Angeli P.
    Bernardi M.
    Villanueva C.
    Francoz C.
    Mookerjee R.P.
    Trebicka J.
    Krag A.
    Laleman W.
    Gines P.
    [J]. JOURNAL OF HEPATOLOGY, 2018, 69 (02) : 406 - 460
  • [4] European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
  • [5] EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
    Lampertico P.
    Agarwal K.
    Berg T.
    Buti M.
    Janssen H.L.A.
    Papatheodoridis G.
    Zoulim F.
    Tacke F.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 67 (02) : 370 - 398
  • [6] Assessing the performance of the EQ-VAS in the NHS PROMs programme
    Feng, Yan
    Parkin, David
    Devlin, Nancy J.
    [J]. QUALITY OF LIFE RESEARCH, 2014, 23 (03) : 977 - 989
  • [7] Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
    Herdman, M.
    Gudex, C.
    Lloyd, A.
    Janssen, M. F.
    Kind, P.
    Parkin, D.
    Bonsel, G.
    Badia, X.
    [J]. QUALITY OF LIFE RESEARCH, 2011, 20 (10) : 1727 - 1736
  • [8] Global burden of hepatitis B virus: current status, missed opportunities and a call for action
    Hsu, Yao-Chun
    Huang, Daniel Q.
    Nguyen, Mindie H.
    [J]. NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2023, 20 (08) : 524 - 537
  • [9] Validation of the "Six-and-Twelve" Prognostic Score in Transarterial Chemoembolization-Treated Hepatocellular Carcinoma Patients
    Kaewdech, Apichat
    Sripongpun, Pimsiri
    Cheewasereechon, Natcha
    Jandee, Sawangpong
    Chamroonkul, Naichaya
    Piratvisuth, Teerha
    [J]. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2021, 12 (02) : E00310